Laekna, Inc. (HKG:2105)
Hong Kong · Delayed Price · Currency is HKD 15.34
+0.84 (5.79%)
At close: Mar 27, 2026
Laekna Revenue
In the year 2025, Laekna had annual revenue of 106.72M CNY with 20,266.22% growth. Laekna had revenue of 4.51M in the half year ending June 30, 2025, with 1,958.90% growth.
Revenue
106.72M CNY
Revenue Growth
+20,266.22%
P/S Ratio
54.02
Revenue / Employee
1.27M CNY
Employees
84
Market Cap
6.42B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.72M | 106.20M | 20,266.22% |
| Dec 31, 2024 | 524.00K | 54.00K | 11.49% |
| Dec 31, 2023 | 470.00K | 190.00K | 67.86% |
| Dec 31, 2022 | 280.00K | 169.00K | 152.25% |
| Dec 31, 2021 | 111.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.75B |
| Viva Biotech Holdings | 2.01B |
| Ocumension Therapeutics | 895.09M |
| BioDlink International Company | 831.99M |
| Shandong Boan Biotechnology | 829.27M |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |